#CGTDACH2026 | Pharma & Biotech

As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply. Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.

CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.